Analysis Tools
neoplasm
 |
• tumor onset is more rapid than in either single mutant, with almost all females showing mammary gland tumors by 2 weeks postpartum
• tumors exhibit a mixed phenotype, with areas resembling basaloid hyperplasia and squamous metaplasia
• tumors exhibit morphological, gene and protein expression profile characteristics of basal breast cancers; they are HER2/ErbB2, ER, and PR negative, and express metastasis-associated genes
• treatment with the Wnt and Met inhibitors ICG-001 or PHA 665752 results in a moderate decrease in mammary gland tumor volume, treatment with a combination of these or with a small molecule inhibitor AMD3100, an agonist of CXCR4 receptor, strongly suppresses tumor onset up to 16 days, and treatment with all three shows the strongest inhibition in tumor size
|
|
|
• in a few cases, virgin females develop small tumors
|
endocrine/exocrine glands
|
|
• mammary gland tissues of breeding females show an expansion of CD24+/CD29(medium) and CD24+/CD49(hi) cells and depletion of CD24(low)/CD29+ cells, indicating expansion of a population of cells with progenitor and stem cell characteristics
|
|
|
• production of milk protein beta-casein after pregnancy is not detected indicating a block in normal mammary gland differentiation
|
|
|
• lobuloalveolar hyperplasia
|
|
|
• tumor onset is more rapid than in either single mutant, with almost all females showing mammary gland tumors by 2 weeks postpartum
• tumors exhibit a mixed phenotype, with areas resembling basaloid hyperplasia and squamous metaplasia
• tumors exhibit morphological, gene and protein expression profile characteristics of basal breast cancers; they are HER2/ErbB2, ER, and PR negative, and express metastasis-associated genes
• treatment with the Wnt and Met inhibitors ICG-001 or PHA 665752 results in a moderate decrease in mammary gland tumor volume, treatment with a combination of these or with a small molecule inhibitor AMD3100, an agonist of CXCR4 receptor, strongly suppresses tumor onset up to 16 days, and treatment with all three shows the strongest inhibition in tumor size
|
|
|
• in a few cases, virgin females develop small tumors
|
integument
|
|
• mammary gland tissues of breeding females show an expansion of CD24+/CD29(medium) and CD24+/CD49(hi) cells and depletion of CD24(low)/CD29+ cells, indicating expansion of a population of cells with progenitor and stem cell characteristics
|
|
|
• production of milk protein beta-casein after pregnancy is not detected indicating a block in normal mammary gland differentiation
|
|
|
• lobuloalveolar hyperplasia
|
|
|
• tumor onset is more rapid than in either single mutant, with almost all females showing mammary gland tumors by 2 weeks postpartum
• tumors exhibit a mixed phenotype, with areas resembling basaloid hyperplasia and squamous metaplasia
• tumors exhibit morphological, gene and protein expression profile characteristics of basal breast cancers; they are HER2/ErbB2, ER, and PR negative, and express metastasis-associated genes
• treatment with the Wnt and Met inhibitors ICG-001 or PHA 665752 results in a moderate decrease in mammary gland tumor volume, treatment with a combination of these or with a small molecule inhibitor AMD3100, an agonist of CXCR4 receptor, strongly suppresses tumor onset up to 16 days, and treatment with all three shows the strongest inhibition in tumor size
|
|
|
• in a few cases, virgin females develop small tumors
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| breast cancer | DOID:1612 |
OMIM:114480 |
J:206839 | |
